Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-11-11 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Cellid' covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business operations, management discussions, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-11 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, and purpose of the event, and mentions that IR materials will be posted on the company website and the KRX KIND system. Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it fits the criteria for a Report Publication Announcement or a general regulatory filing announcement regarding an event.
2022-10-27 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Cellid) announcing a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, the counterparty, the duration, and the nature of the agreement (manufacturing and technology transfer for a CAR-T therapy). Since this is a specific regulatory disclosure of a material contract and does not fit into categories like earnings releases, financial reports, or shareholder communications, it is classified as a general Regulatory Filing (RNS).
2022-09-27 Korean
투자판단관련주요경영사항(국책과제 선정(아데노바이러스 벡터 플랫폼 기반 COVID-19 변이 대응 백신의 임상 1/2상 개발))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Cellid) regarding a 'major management matter' (투자판단 관련 주요경영사항), specifically the selection for a government-funded research project related to COVID-19 vaccine development. It details the project scope, funding, and objectives. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a standard regulatory disclosure of a material event, it falls under the 'Regulatory Filings' category.
2022-08-24 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Cellid' (주식회사 셀리드) covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial information, business operations, management discussions, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-12 Korean
투자판단관련주요경영사항(COVID-19 예방 백신 AdCLD-CoV19-1 OMI의 제1/2상 임상시험 계획(IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the approval of a Phase 1/2 clinical trial (IND) for a COVID-19 vaccine by the Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory disclosure of a material event (clinical trial approval) that does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-08-04 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.